Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S432000
Reexamination Certificate
active
07105566
ABSTRACT:
The invention provides in one embodiment a method for treating vascular trauma. The method can include administering to an individual undergoing vascular trauma an effective amount of a retinoic acid receptor (RAR) antagonist or an RAR inhibitor. The methods can be used to lower serum triglycerides in a patient undergoing an invasive vascular procedure such as vascular surgery.
REFERENCES:
patent: 5776699 (1998-07-01), Klein et al.
patent: 5877207 (1999-03-01), Klein et al.
patent: 5919970 (1999-07-01), Song et al.
patent: 5958954 (1999-09-01), Klein et al.
patent: 5973007 (1999-10-01), Demarchez et al.
patent: 6037488 (2000-03-01), Song et al.
patent: 6133309 (2000-10-01), Bollag et al.
patent: 6218128 (2001-04-01), Klein et al.
patent: 6228848 (2001-05-01), Klein et al.
patent: 6355806 (2002-03-01), Johnson et al.
patent: 6521641 (2003-02-01), Klein et al.
patent: 6545049 (2003-04-01), Canan-Koch et al.
patent: 2002/0193403 (2002-12-01), Yuan et al.
patent: 2005/0009868 (2005-01-01), Underhill et al.
patent: WO94/14777 (1994-07-01), None
patent: WO 99/33821 (1999-07-01), None
patent: WO 02/22113 (2002-03-01), None
Fisher , Edwin., Effect of hypertension on cholesterol altherosclerosis in diabetic rabbits, (abstract only), Laboratory Investigation, (1961) vol. 10, pp. 361-372.
Konneh et al., Red wine derived compounds and their putative antiatherogenic . . . , (abstract only), Colloques-Institut National de la Recherche Agronomique (1988), vol. 87(polyphenols 96), pp. 105-115.
Kalinowski et al., Intra-arterial application of the ACE inhibitor ramipril using . . . , RoFO. Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, (Nov. 1998) vol. 169(5), pp. 532-536.
Johnson et al., Peripheral vascular complications of coronary angioplasty by . . . , (abstract only), Catheterization and cardiovascular diagnosis, (Mar. 1994), vol. 31(3), pp. 165-172.
de Man et al., “Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastin,”Arterioscerl. Thromb. Vasc. Biol. 20:744-750 (2000).
Dol et al., “Simvastatin inhibits myointimal hyperplasia following carotid artery injury in cholesterol-fed rabbits,”Blood Coagulation Fibrinolysis7:772-778 (1996).
Hoogerbrugge et al., “Hypertriglyceridemia enhances monocyte binding to endothelial cells in NIDDM,”Diabetes Care19:1122-1125 (1996).
Horlein et al., “Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor,”Nature277:397-404 (1995).
Klein et al., “Recruitment of nuclear receptor corepressor and coactivator to the retinoic acid receptor by retinoid ligands. Influence of DNA-heterodimer interactions,”J. Biol. Chem. 275:19401-19408 (2000).
Kurokawa et al., “Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding,”Nature371:528-531 (1994).
Monti et al., “Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine,”Am. J. Physiol. Heart Circ. Physiol. 281:H1122-H1130 (2001).
Mouchon et al., “Allosteric regulation of the discriminative responsiveness of retinoic acid receptor to natural and synthetic ligands by retinoid X receptor and DNA,”Mol. Cell. Biol. 19-3073-3085 (1999).
Mussoni et al., “Hypertriglyceridemia and regulation of fibrinolytic activity,”Arterioscler. Thrombosis12:19-27 (1992).
Rachez et al., “Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex,”Nature398:824-828 (1999).
Shinohara et al., “Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats,”Atherosclorsis136:275-279 (1998).
Thacher et al., “Therapeutic applications for ligands of retinoid receptors,”Current Pharm. Design6:25-58 (2000).
Whitfield et al., “Steroid hormone receptors: evolution, ligands and molecular basis of biologic function,”J. Cell. Biochem. Suppl. 32/33:110-122 (1999).
Chandraratna Roshantha A.
Dang Tuong P.
Loh Sheng Z.
Yuan Yang-Dar
Allergan Inc.
Kim Vickie
LandOfFree
Methods of treatment during vascular procedures does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment during vascular procedures, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment during vascular procedures will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3566724